Injectable Bioresorbable Subcutaneous Contraceptive
mdc-WWM
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): MedinCell
Details
- API: Not Yet Finalized - Progestin
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Proprietary Gel
- Regimen: 1 Injection/6 Months
- MPT: Not Potential MPT
- Promising Attributes: Developer indicates that the product would be low cost, control burst through a "gel pump", and would hit a 6-month duration, which has been identified as a desirable duration by users
Product Status
Active Pre-Clinical Developed Confirmed by Developer Pipeline Report (Sept 2024)
History
2017: MedinCell announces initial grant from Gates Foundation to support the development of a long-acting contraceptive using their proprietary BEPO drug delivery technology. Product later refined to be a subcutaneous "gel pump" that would slowly release a progestin.
2019: Developer announces additional funding to support pre-clinical and clinical activities through Phase I
2022: MedinCell announces intent to initiate Ph I trial in 2023 & receipt of $4M in additional funding from the Gates Foundation
2024: Pipeline reports in 2024 indicates that the trial did not initiate as planned - product is still in pre-clinical. Status states "CMC activities ongoing for initiation of clinical phase 1 activities in 2025"